To earn credit, a pre-test is required. Click here to access activity pre-test:
If you do not want to earn credit but want to view the video, read the activity overview below.
It is required you read the activity overview. Once you have scrolled to the end, click to confirm, and you will be able to watch the video.
Treatment- and Disease-Related Cardiotoxicity in the Oncology Setting
A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians
Meniscus Educational Institute
Advanced Practitioner Society of Hematology and Oncology
© 2014, Meniscus Educational Institute. All rights reserved.
Jean-Bernard Durand, MD, FCCP, FACC
Activity Rationale and Purpose
Cardiovascular (CV) toxicity is a potential short- or long-term complication of various anticancer therapies. Assessment of the prevalence, type and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic and guidelines for preventing, monitoring and treating cardiac side-effects are a major medical need. This activity will discuss common treatment-related cardiac abnormalities, including appropriate tools for diagnostic evaluation, pharmacologic and nonpharmacologic approaches to prevention and management of common cardiac events in cancer patients. The discussion of the principles of interprofessional management of cardiac events in cancer patients describes the application of risk analysis, prevention, early identification of signs and symptoms, and individualized treatment planning for cancer patients at risk of developing disease- or treatment-related cardiac events.
The activity’s target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
After completing this educational activity, participants should be able to:
Statement of Credit—Participants who successfully complete this activity (including completion of the post-test with a passing score of at least 70% and evaluation form) will receive a statement of credit.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Meniscus Educational Institute and Advanced Practitioners Society for Hematology and Oncology (APSHO) and JADPRO. The Meniscus Educational Institute is accredited by the ACCME to provide continuing medical education for physicians.
The Meniscus Educational Institute designates this enduring webcast for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity for 1.0 contact hours is provided by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.0 contact hours.
The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 1.0 contact hours, is 0429-9999-15-008-H01-P.
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by Meniscus Educational Institute (MEI) may contact MEI in writing at 3131 Princeton Pike, Bldg 1B Suite 205A, Lawrenceville, NJ 08648. A written response will be provided within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Vice President, MEI may be made for a second level of review.
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Jean-Bernard Durand, MD, FCCP, FACC has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Terry Logan, CCMEP, has nothing to disclose.
Molly Thompson has nothing to disclose.
Lynn Rubin has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lead Nurse Planner
Rita Wickham, PhD, RN, AOCN®, has received honoraria from Genentech.
Peg Fields, MSN, ACNP-BC, AOCNP has nothing to disclose.
Moshe C. Ornstein, MD, MA has nothing to disclose.
William A Bonnell, RPh has nothing to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
Dr. Durand will not discuss off-label and/or investigational use in his presentation.
I confirm that I have read the above information.
If you do not want to earn credit but want to view the video, click here: